Insights

Innovative Drug Delivery KAER Biotherapeutics has developed the patented SUPRAER aerosol technology capable of delivering viscous and high molecular weight therapeutics deep into the lungs, creating an opportunity to introduce advanced aerosolized treatments to clinical settings seeking novel lung therapy solutions.

Respiratory Focus Specializing in surfactant aerosol therapies for neonatal and adult respiratory distress conditions like NRDS and ARDS, KAER operates in a high-need market with significant potential for expanding treatment options for critical care hospitals and respiratory specialists.

Market Expansion Potential The company's focus on addressing unmet needs such as ARDS and other lung diseases presents a sales opportunity to partner with healthcare providers, research institutions, and biotech firms involved in respiratory illness management and drug development.

Technological Differentiation KAER’s ability to aerosolize viscous and suspensions of high molecular weight agents through SUPRAER provides a competitive edge, making it attractive for collaborations with pharmaceutical companies developing targeted aerosol therapies for complex lung diseases.

Growth and Funding With a revenue range of 1 to 10 million dollars and ongoing innovation in aerosol delivery, KAER presents an opportunity for strategic investments, licensing, or partnership deals to scale their technology and accelerate adoption in the respiratory therapeutics market.

KAER Biotherapeutics Corporation Tech Stack

KAER Biotherapeutics Corporation uses 8 technology products and services including Open Graph, Webpack, Module Federation, and more. Explore KAER Biotherapeutics Corporation's tech stack below.

  • Open Graph
    Content Management System
  • Webpack
    Development
  • Module Federation
    Development
  • Sirvoy
    Hotel Management
  • Google Cloud
    Infrastructure As A Service
  • JSON-LD
    Javascript Frameworks
  • WebsiteBuilder
    Page Builders
  • X-Content-Type-Options
    Web & Portal Technology

Media & News

KAER Biotherapeutics Corporation's Email Address Formats

KAER Biotherapeutics Corporation uses at least 1 format(s):
KAER Biotherapeutics Corporation Email FormatsExamplePercentage
FLast@kaerbio.comJDoe@kaerbio.com
39%
Last@kaerbio.comDoe@kaerbio.com
11%
FLast@kaerbio.comJDoe@kaerbio.com
39%
Last@kaerbio.comDoe@kaerbio.com
11%

Frequently Asked Questions

Where is KAER Biotherapeutics Corporation's headquarters located?

Minus sign iconPlus sign icon
KAER Biotherapeutics Corporation's main headquarters is located at 926 South Andreasen Drive Escondido, California 92029 United States. The company has employees across 1 continents, including North America.

What is KAER Biotherapeutics Corporation's phone number?

Minus sign iconPlus sign icon
You can contact KAER Biotherapeutics Corporation's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is KAER Biotherapeutics Corporation's official website and social media links?

Minus sign iconPlus sign icon
KAER Biotherapeutics Corporation's official website is kaerbio.com and has social profiles on LinkedIn.

What is KAER Biotherapeutics Corporation's NAICS code?

Minus sign iconPlus sign icon
KAER Biotherapeutics Corporation's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does KAER Biotherapeutics Corporation have currently?

Minus sign iconPlus sign icon
As of February 2026, KAER Biotherapeutics Corporation has approximately 3 employees across 1 continents, including North America. Key team members include Mechanical Engineer: X. H.. Explore KAER Biotherapeutics Corporation's employee directory with LeadIQ.

What industry does KAER Biotherapeutics Corporation belong to?

Minus sign iconPlus sign icon
KAER Biotherapeutics Corporation operates in the Medical Equipment Manufacturing industry.

What technology does KAER Biotherapeutics Corporation use?

Minus sign iconPlus sign icon
KAER Biotherapeutics Corporation's tech stack includes Open GraphWebpackModule FederationSirvoyGoogle CloudJSON-LDWebsiteBuilderX-Content-Type-Options.

What is KAER Biotherapeutics Corporation's email format?

Minus sign iconPlus sign icon
KAER Biotherapeutics Corporation's email format typically follows the pattern of FLast@kaerbio.com. Find more KAER Biotherapeutics Corporation email formats with LeadIQ.

When was KAER Biotherapeutics Corporation founded?

Minus sign iconPlus sign icon
KAER Biotherapeutics Corporation was founded in 2008.

KAER Biotherapeutics Corporation

Medical Equipment ManufacturingCalifornia, United States2-10 Employees

KAER Biotherapeutics is a preclinical aerosol drug delivery company addressing the needs of respiratory ailments in clinics and hospitals. 

KAER is primarily focused on the provision of surfactant aerosol therapy for patients in respiratory distress related to the absence of sufficient active lung surfactant. These patients include prematurely born infants whose lungs are not producing sufficient low surface tension surfactant to enable their airways to fully open and support adequate respiratory function. Neonatal Respiratory Distress Syndrome, NRDS, is the major cause of mortality in prematurely born neonates. At any age, but especially in the elderly, insults to the lungs and body can induce acute respiratory distress.  Acute respiratory distress syndrome, ARDS, results from abnormal surfactant production and inflammation-induced degradation of surfactant. When this is the result of a direct insult to the lungs, such as pneumonia or smoke inhalation, it is denoted acute lung injury, ALI.  ALI can rapidly deteriorate into ARDS.  There are no approved drugs for patients with ARDS. Despite the best life support, 40% of these patients die.

KAER developed patented enabling aerosol generation, processing and delivery technology to address these needs. KAER’s SUPRAER technology aerosolizes liquids containing the surfactant or other active pharmaceutical agent and delivers them as concentrated pure fine particle solid-phase aerosols suitable for deep lung deposition.  SUPRAER is differentiated by its ability to aerosolize viscous fluids and suspensions of high molecular weight agents. High masses of fine particle therapeutic aerosols therapies can be rapidly administered at clinically relevant doses. 

KAER is seeking partners to facilitate the rapid implementation of this the aerosol delivery technology for the treatment of respiratory distress, IPF, hospital acquired pneumonia, TB, NSCLC and other debilitating lung diseases.

Section iconCompany Overview

Headquarters
926 South Andreasen Drive Escondido, California 92029 United States
Phone number
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2008
Employees
2-10

Section iconMedia & News

Section iconFunding & Financials

  • $1M$10M

    KAER Biotherapeutics Corporation's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    KAER Biotherapeutics Corporation's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.